Comparative Pharmacology
Head-to-head clinical analysis: DIPYRIDAMOLE versus PRAVIGARD PAC COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPYRIDAMOLE versus PRAVIGARD PAC COPACKAGED.
DIPYRIDAMOLE vs PRAVIGARD PAC (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits platelet phosphodiesterase and blocks adenosine reuptake, increasing intracellular cAMP and adenosine levels, thereby inhibiting platelet aggregation; also causes coronary vasodilation.
Pravigard PAC (copackaged) contains pravastatin, an HMG-CoA reductase inhibitor that competitively inhibits the conversion of HMG-CoA to mevalonate, reducing cholesterol synthesis, and buffered aspirin, which irreversibly acetylates cyclooxygenase (COX-1 and COX-2), inhibiting thromboxane A2 synthesis and platelet aggregation.
Dipyridamole immediate-release tablets: 50-100 mg orally 3-4 times daily. Extended-release with aspirin: 200 mg orally twice daily.
PRAVIGARD PAC (copackaged) is not a single drug but a copackaged product containing pravastatin and aspirin. The typical adult dose of pravastatin is 40 mg orally once daily; aspirin is 81 mg orally once daily. Both are taken together as a single daily dose.
None Documented
None Documented
Clinical Note
moderateDipyridamole + Tranilast
"Dipyridamole may increase the anticoagulant activities of Tranilast."
Clinical Note
moderateDipyridamole + Resveratrol
"Dipyridamole may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderateDipyridamole + Nimesulide
"Dipyridamole may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderateDipyridamole + Hydrochlorothiazide
"The risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydrochlorothiazide."
Terminal elimination half-life is 10–12 hours in healthy adults; prolonged to 20–30 hours in hepatic impairment; clinical effect duration correlates with dosing interval.
Pravastatin: 1.5-2 hours (terminal, clinical significance minimal due to prolonged HMG-CoA reductase inhibition); Aspirin: 15-20 minutes (acetylated form), salicylate: 2-3 hours (low dose) to 15-30 hours (high dose, due to saturable metabolism)
Primarily hepatic metabolism (glucuronidation) with enterohepatic recirculation; biliary/fecal excretion accounts for >90% of eliminated drug; renal excretion of unchanged drug is negligible (<5%).
Pravastatin: ~20% renal, ~70% fecal (biliary); Aspirin: renal (dose-dependent, ~50-80% as salicylates, ~10-20% as salicyluric acid)
Category A/B
Category C
Antiplatelet
Antiplatelet/Statin Combination